# Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis

> **NCT00572585** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 60 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** AEB071
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00572585
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2020-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00572585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00572585, "Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00572585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*